Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (38,422)	$ (30,144)
Adjustments to reconcile net loss to net cash used in operating activities:
Compensation expense related to vesting of common stock issued to Xontogeny	0	39
Depreciation	196	137
Stock-based compensation expense	4,118	833
Net amortization of premium on marketable securities	1,174	213
Unrealized (loss) gain from foreign exchange	(18)	79
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(936)	(786)
Accounts payable	4,263	6,506
Other liabilities	2,564	161
Net cash used in operating activities	(27,061)	(22,962)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(440)	(181)
Purchases of available-for-sale marketable securities	(174,853)	(21,718)
Proceeds from sales and maturities of marketable securities	116,587	36,030
Net cash (used in) provided by investing activities	(58,706)	14,131
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from initial public offering	93,000	0
Financing costs paid	(1,907)	0
Proceeds from exercise of stock options	514	1,518
Net cash provided by financing activities	91,607	1,518
Net change in cash and cash equivalents	5,840	(7,313)
Cash and cash equivalents at beginning of period	2,416	9,808
Effect of exchange rates on cash	49	(79)
Cash and cash equivalents at end of period	8,305	2,416
SUPPLEMENTAL NON-CASH DISCLOSURE: NONCASH INVESTING AND FINANCING ACTIVITY:
Purchase of fixed assets in accounts payable	20	41
Deferred offering costs included in accounts payable and accrued liabilities	0	811
Conversion of Series A and B convertible preferred stock to common stock	73,037
Unrealized (loss) gain on available-for-sale marketable securities	$ (235)	$ 87